Four-year follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder

Autor: Joshua P. Radke, Jeffrey R. Wozniak, Christopher W. Lindgren, Judith K. Eckerle, Kristin E. Sandness, Neely C. Miller, Michael K. Georgieff, Ann M. Brearley, Christopher J. Boys, Steven H. Zeisel, Birgit A. Fink, Anita J. Fuglestad
Rok vydání: 2019
Předmět:
Male
Pediatrics
medicine.medical_specialty
Cognitive Neuroscience
Intelligence
Fetal alcohol syndrome
Pathology and Forensic Medicine
law.invention
lcsh:RC321-571
Choline
03 medical and health sciences
0302 clinical medicine
Neurodevelopmental disorder
Cognition
Randomized controlled trial
Double-Blind Method
law
Pregnancy
030225 pediatrics
medicine
Attention deficit hyperactivity disorder
Humans
lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry
Nootropic Agents
business.industry
Working memory
Research
Longitudinal studies
medicine.disease
Executive functions
3. Good health
Memory
Short-Term
Fetal Alcohol Spectrum Disorders
Child
Preschool
Prenatal Exposure Delayed Effects
Pediatrics
Perinatology and Child Health
Randomized controlled trials
Female
Neurology (clinical)
Verbal memory
business
Neurocognitive
030217 neurology & neurosurgery
Follow-Up Studies
Zdroj: Journal of Neurodevelopmental Disorders
Journal of Neurodevelopmental Disorders, Vol 12, Iss 1, Pp 1-13 (2020)
ISSN: 1866-1955
Popis: Background Despite the high prevalence of fetal alcohol spectrum disorder (FASD), there are few interventions targeting its core neurocognitive and behavioral deficits. FASD is often conceptualized as static and permanent, but interventions that capitalize on brain plasticity and critical developmental windows are emerging. We present a long-term follow-up study evaluating the neurodevelopmental effects of choline supplementation in children with FASD 4 years after an initial efficacy trial. Methods The initial study was a randomized, double-blind, placebo-controlled trial of choline vs. placebo in 2–5-year-olds with FASD. Participants include 31 children (16 placebo; 15 choline) seen 4 years after trial completion. The mean age at follow-up was 8.6 years. Diagnoses were 12.9% fetal alcohol syndrome (FAS), 41.9% partial FAS, and 45.1% alcohol-related neurodevelopmental disorder. The follow-up included measures of intelligence, memory, executive functioning, and behavior. Results Children who received choline had higher non-verbal intelligence, higher visual-spatial skill, higher working memory ability, better verbal memory, and fewer behavioral symptoms of attention deficit hyperactivity disorder than the placebo group. No differences were seen for verbal intelligence, visual memory, or other executive functions. Conclusions These data support choline as a potential neurodevelopmental intervention for FASD and highlight the need for long-term follow-up to capture treatment effects on neurodevelopmental trajectories. Trial registration ClinicalTrials.Gov #NCT01149538; Registered: June 23, 2010; first enrollment July 2, 2010
Databáze: OpenAIRE
Externí odkaz: